Rolling Returns
Gland Pharma Ltd.
Every 3-year stretch GLAND has been through — 34 of them, each starting a month after the last. The median returned -8.2% a year, the worst -23.8%, the best 35.4%. A single headline CAGR hides all of that.
Every Holding Period
A rolling window is every possible start date, not one. A five-year window starting in January is a different investment from one starting in February, and over twenty years there are a couple of hundred of them. What follows is the full spread of what each holding period actually produced.
Across 58 separate 1-year holding periods, the median returned 1.9% a year. The worst lost 67.7% a year and the best made 99.1%.
Worst start: May 2022 — -67.7% a year for the 1 years that followed.
Best start: May 2023 — 99.1% a year.
Against the Nifty 50: GLAND came out ahead in 41.4% of the 58 windows both series cover.
Across 34 separate 3-year holding periods, the median returned -8.2% a year. The worst lost 23.8% a year and the best made 35.4%.
Worst start: April 2022 — -23.8% a year for the 3 years that followed.
Best start: May 2023 — 35.4% a year.
Against the Nifty 50: GLAND came out ahead in 17.6% of the 34 windows both series cover.
Windows step forward one month at a time and are measured on month-end adjusted closing prices, so dividends are treated as reinvested. Overlapping windows share months by construction — that is what makes the spread a description of this stock's history rather than a sample of independent trials.
Against The Index
Beating an index once is a result. Beating it across most of the periods an investor could have picked is a pattern. Over 3-year windows, GLAND finished ahead of the Nifty 50 in 17.6% of the 34 periods both series cover.
1-year windows
Ahead in 41.4% of 58 periods.
3-year windows
Ahead in 17.6% of 34 periods.
Each window is compared against the index over the identical calendar months, on the same adjusted basis — not against an assumed rate of return.
How This Is Calculated
Windows step forward one month at a time, so they share most of their months with each other. That is what makes this a description of GLAND's actual history rather than a set of independent trials — and why the spread should not be read as a probability.
Measured on month-end closing prices adjusted for dividends and splits, so dividends count as reinvested. A window that opened or closed mid-month would differ a little in either direction.
GLANDis in today's Nifty 500 universe. Companies that delisted or collapsed are not on this site at all, so the worst outcome shown here is the worst among the survivors.
Measured on data to 2026-08-31, from 2020-11-01. Full definitions are on our methodology page.
HELP CENTER
Everything you need to know about this page and the data presented.
Over 3 years, Gland Pharma Ltd. has been through 34 separate 3 years holding periods — one starting every month. The median returned -8.2% a year, the worst -23.8% and the best 35.4%. A rolling return measures every possible start date instead of one, which is why it answers a question a single headline CAGR cannot: how much the outcome depended on when you happened to buy.
Yes. 67.7% of the 34 3 years periods on record ended below where they started, and the worst of them lost 23.8% a year — the stretch beginning April 2022. The median period returned -8.2% a year.
On this record, yes. 1 year outcomes ranged from -67.7% to 99.1% a year — a spread of 166.8%. 3 years outcomes ranged from -23.8% to 35.4%, a spread of 59.3%. Longer holding periods narrowed the range of results, which is the usual pattern and the reason this page publishes every window rather than one. Narrowing the range is not the same as removing the risk.
In 17.6% of the 34 3 years periods both series cover. Each window is compared against the index over the identical months, not against an assumed index return, so the comparison is a like-for-like record rather than a model.
Windows step forward one month at a time on month-end closing prices adjusted for dividends and stock splits, so dividends are treated as reinvested. A window length is only published once there are at least twelve complete windows behind it — fewer than that describes an anecdote, not a distribution. Overlapping windows share months by construction, which is what makes this a description of the actual history of Gland Pharma Ltd. rather than a sample of independent trials. Companies that delisted are not on this site at all, a survivorship bias worth holding in mind.
That is not a question this page answers, and we do not make recommendations. What it can show you is the full range of what every holding period in the listed history of Gland Pharma Ltd. actually produced — including the worst ones, which most performance figures leave out. Those are records of what happened, not forecasts. A stock that never had a losing decade may still have one, and holding a single company is a materially different risk from holding an index.
Explore Further
GLAND drawdowns and all-time high
The worst fall on record, how long recovery took, and how far the price sits below its peak.
GLAND SIP returns
What a monthly investment would have produced, backtested rather than assumed.
GLAND overview
Price history, wealth journey and how it compares with the index.
Rolling returns for every stock
Run the same question against any company we track.
ReturnScreener is an educational research platform and is not a SEBI-registered investment adviser. Everything on this page is a record of what historical prices did, not a projection and not a recommendation. Past performance does not guarantee future returns. See our methodology and disclaimer.